Abstract: Advances in vaccine formulation have seen a trend towards the use of subunit antigens, ideally incorporated into particulate carriers. These systems are usually in the nanometer size range to facilitate uptake into antigen-presenting cells and to mimic the nature of pathogens. In addition, adjuvants can be incorporated into the same carrier and therefore result in the simultaneous delivery of antigen and adjuvant to the same antigen-presenting cell. A wide variety of particulate carriers have been investigated for vaccine delivery ranging from biological-based particles such as bacterial ghosts and virus-like particles to more simple polymer-or lipid-based systems. In this review we will focus on lipid-based particulate carriers as these offer great potential as regards immune stimulation and due to the simple formulation techniques involved are likely to be more easily scaled-up for manufacture. Another advantage of such systems is versatility in that in addition to the subcutaneous administration of these vaccine formulations, there is also potential for transdermal or even oral delivery. Examples of such delivery systems include liposomes, ethosomes, transfersomes, bilosomes, and immune stimulating complexes. The physico-chemical properties of such systems will be reviewed as will their potential to stimulate immune responses. In addition, we will summarise the recent developments in lipid-based sustained delivery systems for antigens.
INTRODUCTION
The science of vaccine formulation has experienced huge progress and change since the early vaccinations of Jenner in 1796. Due to advances in biotechnology and formulation, vaccines today are more advanced and complex in terms of composition and preparation. A dominating issue in all research into vaccine formulation is that of vaccine safety. As vaccines are commonly administered to healthy but often fragile populations of individuals, such as infants and the elderly, unwanted side-effects or toxicities can not be tolerated and therefore vaccines face strict observation by the licensing bodies.
Early traditional vaccines consisted of live-attenuated pathogens, inactivated toxins or heat-killed pathogens. The live-attenuated vaccines in particular have proven to be highly effective and to achieve good protection [1] . However, the administration of attenuated pathogens always bears the risk that the organism might revert back into its virulent form. In addition, the administration of liveattenuated vaccines to immunocompromised individuals is not advisable. Toxoid and killed whole pathogen vaccines, whilst also being effective, produce local and sometimes even systemic toxicities that have resulted in these types of vaccines being less favoured as methods for producing new vaccines. An additional challenge is all these methods rely on the cultivation of the pathogen in the laboratory, which can prove to be time-consuming, and in some cases no successful protocol for cultivation has been successfully established [2] .
In recent years there has been an emphasis on the development of subunit vaccines. Subunit vaccines only contain *Address correspondence to this author at the School of Pharmacy, Adams Building, 18 Frederick Street, Dunedin, New Zealand; Tel: +64 3 479 7877; Fax: +64 3 479 7034; E-mail: sarah.hook@stonebow.otago.ac.nz the immunogenic fraction of a virulent pathogen in the form of a peptide, protein, or DNA. The administration of such pathogen fragments eliminates the risk of pathogens reverting back to their virulent form and the toxicities associated with using whole pathogens or inactivated toxins are removed. In addition, subunit vaccines have advantages in terms of vaccine production and licensing since a welldefined pathogen fragment can more easily be produced cheaply and consistently and a fast characterisation of the formulation is facilitated [3, 4] .
The major disadvantage of subunit vaccines is poor immunogenicity. Since a very pure formulation is administered, the pathogen fragment may not be recognised by the immune system of the host as 'dangerous' [5] . This frequently results in the subunit antigen being ignored by the immune system, or, if administered frequently, may lead to the development of tolerance towards the antigen. In order to achieve an effective activation of the immune system, the addition of an adjuvant that stimulates an effective immune response towards the subunit antigen is required.
An additional challenge in vaccine development today is that the vaccine not only must be safe and immune stimulatory but also that it must stimulate the appropriate immune response. Protection against many infections can be mediated predominantly by antibodies and as these are readily produced in response to exogenous antigen vaccines have been a great success in providing protection against long list of infectious diseases [2] . However some of the major diseases for which effective vaccines are not yet readily available, for example HIV, tuberculosis and malaria, require cellular immunity in addition to antibody for protection [6] . CD8 mediated responses in particular are difficult to target as exogenous vaccine antigens do not generally access the class I MHC antigen presentation pathway [7] . However, increased understanding of antigen cross presentation [8] has revealed ways in which vaccine formulations can be modi-fied in order to optimise presentation of vaccine antigens on MHC class I. For example inclusion of cationic lipids into liposomes can lead to the formation of pH sensitive liposomes which can result in 'proton sponge-mediated escape' from the endosome and entry into the cytoplasm [9] . Saponins, which have been included as adjuvants in a number of lipidic vaccine formulations have also been suggested to be able to facilitate endosomal escape [10] .
LIPID BASED PARTICULATE DELIVERY SYSTEMS
Particulate vaccines offer a number of advantages for the delivery of subunit vaccine antigens. The first of these is that antigens and adjuvants can be entrapped within the particles. Peptides and DNA have short half lives in vivo and protecting these molecules from enzymatic degradation can improve vaccine efficacy [11] . Depending on the physicochemical characteristics of the particles, oral or transdermal delivery of the vaccine may also be an option. Adjuvants can additionally be incorporated into the particulate carrier to further improve vaccine efficacy as the possibility exists that both antigen and adjuvant will be taken up by the same antigen presenting cell (APC) [12] .
It may also be beneficial for vaccine efficacy if the particles have features similar to those of a pathogen in terms of size and surface morphology. The particles could then be taken up by cells of the immune system such as APCs using methods normally employed for pathogens [13] . Therefore particulate vaccine carriers are usually prepared in the nanometer and micrometer size range, which is similar to that of pathogens. These dimensions are believed to facilitate uptake into antigen presenting cells since a size less than 10 μm has been described as being beneficial for uptake [14] . Other surface features that can be included into or onto the particulate system are repetitive structures or targeting ligands, for example sugars such as mannose, which has been shown to bind to C-type lectins and induce receptormediated endocytosis [15, 16] .
Additionally the kinetics of antigen release from the particles should be optimised. It may be beneficial for induction of the immune response if release of antigen from the vaccine has a similar kinetics to a natural infection. Infections occur locally and the pathogen multiplies at this site and only in some cases spreads systemically. For an ideal vaccine it may therefore be advantageous to develop a formulation that remains at the site of injection and releases the antigen in an immunogenic form over several days or weeks. Such sustained release from a localised depot has been proposed as the mechanism of action for the alum-adjuvanted vaccines, where the antigen is adsorbed onto an aluminium gel. It was thought that the desorption process of the antigen from alum occurs slowly, thereby providing a localised depot. However, this hypothesis of sustained release from alum-based vaccines has been debated in the literature and to date no firm conclusion as to whether sustained release occurs has been reached and other mechanisms for immune stimulation have been proposed [17, 18] .
A wide variety of particulate delivery systems in the nanometer and micrometer size range have been investigated for vaccine delivery. These range from biological systems such as virus like particles (VLP) [19, 20] and bacterial ghosts [21] to systems based on lipids and polymers. While the non-biological systems do not have the intrinsic immunogenicity of the biological systems, they have the advantage of simplicity and ease of manufacture, which is an important characteristic of any vaccine formulation and should not be overlooked. The lack of immunogenicity may also be advantageous as it makes it unlikely that an unwanted immune response against the vaccine carrier will be mounted. In addition, if well defined reagents are used, licensing can progress more swiftly.
In this review we will examine lipid-based nanoparticulate systems for vaccine delivery ( Table 1) . Most lipids are well-tolerated when compared to other synthetic components. Phospholipids and cholesterol are often utilised in the preparation of liposomes which are one example of nanoparticulate lipid-based carriers. These lipids occur naturally in the human body and are therefore less of an issue than chemical polymers or other synthesised components in terms of biocompatibility.
Liposomes
Since their first observation by Bangham in the 1960s, liposomes have been investigated by numerous researchers for their potential as drug or vaccine delivery systems. Bangham was the first to report that the dispersion of phospholipid in excess of aqueous solution resulted in the formation of particles that exhibited one or more concentric bilayers which were separated by aqueous compartments [22] . The hypothesis, that these particulate carriers would be suitable for drug delivery, has proven to be correct and a number of liposomal formulations are on the market. In addition, liposomes also proved to be interesting for vaccine delivery [23] [24] [25] [26] because of their small size and versatility.
Both hydrophilic and hydrophobic antigens can be incorporated into the liposome structure [27] , although the incorporation efficiency may vary depending on the choice of lipids, the preparation technique, the physico-chemical characteristics of the bioactive, and the overall charge of the liposome. For example, high entrapment efficiencies for protein antigen and plasmid DNA have been reported for liposomes formed by the dehydration-rehydration procedure [28] . In addition, the antigen can also be chemically attached to the surface of the delivery system. Altogether, this shows that liposomes are a very versatile delivery system [29] .
In order to produce liposomes several techniques have now been established. The most common method to prepare liposomes is the Bangham method [22] , but also variations of this method, a dehydration-rehydration [30] and an ethanol injection method for rapid production of liposomal structures have been developed [31] , to name some examples. The size of liposomes can range from around 100 nm to several micrometers. The scale-up process for liposomal preparations is still challenging. In particular the consistent formulation of the required size range of liposomes is difficult and long-term stability of the final product is still an issue as liposomes tend to fuse and form larger particles over time. The visualisation of liposomes is accomplished by the implementation of different techniques; commonly transmission electron microscopy (TEM) after negative staining, cryo-FESEM, freeze-fracture TEM, atomic force microscopy (AFM) [32, 33] or environmental scanning electron microscopy (ESEM) [34] are used.
The efficacy of liposomal vaccine formulations has been investigated by numerous research groups. Liposomes investigated range from simple phosphatidylcholine (PC) liposomes [35] to highly modified liposomes [29] . Cationic liposomes have also been investigated with regard to DNA immunisation, and different cationic lipids such as DCcholesterol, DOTMA, and dimethyldioctadecylammonium (DDA) have been utilised [30, 36] . Other groups have focused on the formulation of stabilised stealth liposomes containing cationic lipids [37] .
Liposomes are usually given by injection; however intranasal delivery has also been examined for delivery of tetanus toxoid [38] , and hepatitis B surface antigen DNA [39] . Oral delivery has also been examined however this is more problematic due to the potential for breakdown of liposomes following exposure to bile salts [40] . A number of formulations have progressed as far as clinical testing, including a liposomal vaccine against non-small lung cancer [41] and a malaria vaccine [42] .
Immune-Stimulating Complexes (ISCOMs)
Immune-stimulating complexes or ISCOMs are lipidic nanoparticulate vaccine antigen carriers consisting of a phospholipid, cholesterol, and Quillaja saponins derived from the South American tree Quillaja saponaria Molina (Rosaceae) [43, 44] . If no antigen is present in the formulation, the approximately 40 nm sized 'soccer-ball' structures carry an overall negative charge and are termed ISCOM matrix, whereas when an antigen is incorporated into the particle, the term ISCOM is utilised. ISCOMs were first observed by researchers using transmission electron microscopy but were regarded as microscopic artefacts at the time [45, 46] . Only in 1984 were the small structures re-discovered by Morein and co-workers and their potential as vaccine delivery systems investigated [47] . Since then, ISCOMs have been investigated in great depth.
ISCOMs can be produced by a variety of techniques: dialysis [48] , centrifugation [47] , lipid film hydration [49] , ethanol [50] and ether injection [51] , with each of these methods requiring a method-specific ratio of Quillaja saponins:cholesterol:phospholipids to obtain well-defined particulate carriers [52] .
Due to their small, virus-like size, ISCOMs have great potential as vaccine carriers, especially because ISCOMs have the adjuvant function of the Quillaja saponins in-built into the system. If the system lacks Quillaja saponins only liposomal structures are produced, showing that Quillaja saponins are an essential component in the formulation of ISCOMs. The particulate carriers are usually viewed using transmission electron microscopy after negative-staining.
ISCOMs have been extensively studied with regard to their immunogenicity, and it has been demonstrated that IS-COM-based vaccines are able to induce both Th1 and Th2 responses, with the production of a variety of Th1 and Th2 cytokines [53] [54] [55] . Since ISCOM-based vaccines have not only been reported for parenteral, but also mucosal [56, 57] and oral [58] delivery of antigens, they have become particularly attractive as vaccine delivery systems. One issue with the use of ISCOMs as a vaccine delivery system is the incorporation of antigen. ISCOM matrix has an open cage-like structure and while antigens with an amphiphilic character are readily incorporated into the lipid structure, loading of very hydrophilic antigens is more problematic [59] due to the lack of driving force of the hydrophilic antigen to attach to the cage-like structure of the ISCOM. The incorporation of very lipophilic antigens often results in aggregation [45] .
Several ISCOM-based vaccines are on the market in the veterinary sector [44, [60] [61] [62] and ISCOM-based vaccines for cancer therapy have undergone human clinical trials [63] .
Cationic Cage-Like Complexes (PLUSCOMs)
PLUSCOMs are cationic cage-like complexes that have a similar appearance and are in the same size range as their anionic ISCOM counterparts [64] . In order to achieve an overall cationic charge of the particulate carrier, cholesterol was replaced with its cationic derivative DC-cholesterol. A pseudo-ternary phase diagram was established to systematically determine the optimal ratio of Quillaja saponins, DCcholesterol and phospholipid and to confirm the formation of cationic ISCOM-like structures. The PLUSCOMs were prepared using the same lipid film hydration techniques that was used for ISCOMs.
The formation of cationic cage-like complexes using DOTAP as a positively-charged lipid has also been performed [65] , however these particles did not display a positive surface charge.
The advantage of the cationic system is that negativelycharged antigens, including peptides, protein and DNA, can be readily adsorbed onto the surface of the colloidal particle [44, 64, 66] . The efficacy of PLUSCOMs in stimulating immune response was investigated in mice using ovalbumin as a model antigen [66] .
Transfersomes
Transfersomes are 'ultradeformable' vesicles which were first introduced by Cevc and Blume in 1992 [67] . Transfersomes are 100 to 200 nm particles consisting of phospholipids but additionally containing surfactants such as sodium cholate, sodium deoxycholate, or different types of sorbitan monolaurate or polyoxyethylensorbitan monolaurate. They can be easily prepared by the lipid film hydration method which is commonly used for the preparation of liposomes. The surfactants are incorporated into the lipid bilayers and are thought to be responsible for the deformability of the particles. Such surfactants have been termed "edgeactivators" [68] because they destabilise the lipid bilayer of the vesicles and increase the deformability of the vesicles by lowering the interfacial tension [69, 70] . This mechanism is thought to enable the vesicles to facilitate transdermal delivery. Transfersomes have been used for transdermal delivery of drugs and vaccines. In particular, studies have revealed that transfersomes may be an interesting delivery system for transdermal immunisations, since transfersomes loaded with FITC-BSA were able to elicit anti-BSA specific antibody responses [71] . In addition to traditional transfersomes, cationic transfersomes containing the cationic lipid DOTMA have been investigated as a potential topical vaccine against hepatitis B [72] .
Ethosomes
Similar to liposomes, ethosomes consist of phospholipids and water, but at the same time contain relatively large amounts of ethanol (20-45%) . Ethosomes are made using the hydration method [73] . The size of the ethanol-containing particles depends on both the ethanol content in the formulation as well as the phospholipid concentration. In comparison to liposomes, ethosomes have been reported to display a smaller size (around 140 to 230 nm) which is believed to be an effect of the presence of ethanol in the vesicles [73] . In terms of stability, ethanol has been reported to exhibit a stabilising effect and to delay the formation of liposome aggregates. Ethanol is good permeation enhancer; hence, the high ethanol content is believed to achieve a disorder in the stratum corneum which facilitates transdermal drug transport [74] . To date, the delivery of drugs, for example lamivudine, salbutamol sulphate, ketotifen, erythromycin, testosterone, bacitracin and cannabidiol, has been reported in the literature. In addition, ethosomes may also provide a novel delivery system for subunit antigens if it can be ensured that the high ethanol content in the formulation does not harm the antigen. The delivery of hepatitis B antigen encapsulated into ethosomes and the immune response generated by this vaccine has been investigated and reported in the literature [75] .
Bilosomes
Bilosomes are non-ionic surfactant vesicles which contain bile salts such as deoxycholate. Bilosomes were first described by Conacher et al. (2001) [76] . Similar to liposomes, ISCOMs and ethosomes, bilosomes are prepared using the film hydration method. The size of the vesicles has been reported to be typically around 200 nm [77] . The major advantage of this delivery system is the potential for oral administration [78] . As bilosomes already contain bile salts within the vesicle layers they have been reported to be stable upon exposure to endogenous bile salts in the gastrointestinal tract [79] . Bilosomes have since been investigated in mice using a number of different antigens including tetanus toxoid [78] , BSA [79] , synthetic peptides [76] and haemagglutinin antigen [80] . At the present time there have been no reports on human clinical trials of bilosome vaccines.
Niosomes
Niosomes are unilamellar vesicles prepared from nonionic surfactants and are also referred to as non-ionic surfactant vesicles (NISVs). The advantage of these colloidal particles is higher stability compared to liposomal formulations. Brewer and Alexander [81] investigated the humoral immune response of different antigens incorporated into NISVs compared to emulsified CFA in different strains of mice, and NISVs proved to be equally effective in stimulating IgG antibody responses. Similarly, Gupta et al. [82] discovered that compared to CFA or an alum-adjuvanted vaccine, the niosome-based preparation was able to induce equal immune responses in murine models and New Zealand white rabbits.
Lipid Implants
Lipid implants that release self-assembling lipidic particles have also been investigated for vaccine delivery. An advantage of a sustained release system would be the potential for reducing, or removing, the need for booster immunisations which are commonly required with subunit vaccines. However care must be taken to ensure the vaccine antigen in released in an immunogenic form to lead to stimulation of immunity and not tolerance.
In early studies, Khan et al. [83, 84] developed an implantable pellet prepared from cholesterol or a mixture of cholesterol and phospholipid containing a model antigen. The immune response towards the model antigen was investigated based on the production of antigen-specific antibodies [83] . Since then, several groups have investigated the potential of lipid implants or pellets with regards to their function as a delivery system for drugs or vaccines. Lipid implants based on triglycerides or mixtures of triglycerides with cholesterol have been successfully utilised for the delivery of interferon-and the release mechanism has been investigated in great depths [85, 86] . Lipid implants produced from phospholipids and cholesterol with the addition of Quil-A as an adjuvant, have also been investigated by Demana et al. (2005) . This work demonstrated that pellets prepared from different ratios of QA:CHOL:PC released a variety of colloidal particles based on the composition of the lipid mixture [87] . These lipid pellets were then further modified [88] and investigated in vivo using ovalbumin as a model antigen in a C57Bl/6 mouse model. The studies revealed that the lipid implants containing antigen and adjuvant were as effective in stimulating immune responses towards the model antigen as were two immunisations given by injection [89] . This promising system was then further modified and other potential adjuvants such as imiquimod and -galactosylceramide were investigated [90] . Finally, the incorporation of cationic DC-cholesterol into the lipid implant system containing Quil-A was attempted which revealed an adjuvant effect of the cationic cholesterol derivative on antibody responses but not on cell-mediated immunity [91] .
SUMMARY AND FUTURE CHALLENGES
Lipid-based particulate delivery systems offer numerous benefits for vaccine delivery. They can be easily made using defined, biocompatible materials and can tolerate the inclusion of a wide spectrum of antigens, adjuvants and targeting ligands. Importantly there is also the potential for needle-free delivery with some of these systems [92] . Needle-free delivery offers obvious advantages in terms of reducing costs of immunisation programmes and increasing compliance. The immune responses generated in response to lipid-based particulate vaccines are diverse with both cellular and humoral responses being generated. This is important as the challenge at present is to formulate vaccines for diseases which require a cytotoxic immune response for protection or therapy, for example HIV, tuberculosis and cancer. Due to an increased understanding of the process by which exogenous antigens enter the MHC class-I pathway new formulation strategies are being implemented to increase the efficacy of vaccines in stimulating CD8 + immune responses. Another exciting area of research is in sustained release particulate formulations. While research in this area is just beginning it has the potential to dramatically alter the way vaccines are formulated and used in the future.
